β3-AR agonist improved LVEDP and end-systolic pressure-volume relation slope, reducing ventricular muscle stiffness and inhibiting Smad2/3, phospho-Smad2/3, and TGF-β1 expression in CHF mice [70]. The gene discussed is SMAD2; the disease is congestive heart failure.